WideMed has obtained clearance from the US Food and Drug Administration to market its home sleep testing device, the Morpheus Ox, in the United States.
The Morpheus Ox measures photoplethysmography (PPG) and blood saturation. The device is capable of producing automatic results from the PPG signal and displaying the results to physicians. Morpheus Ox is based on the Morpheus platform, a Web-based management solution for large amounts of sleep studies from multiple locations over a secure cloud.
“Receiving FDA clearance is a significant achievement for the company,” said Anya Eldan, WideMed’s CEO.